CB-103

Research use only, not for human use.

CB-103 is a orally active inhibitor of notch signaling pathway, with anti-tumor activity. CB-103 has shown the ability to block NOTCH signaling in human T cell acute lymphoblastic leukemia cancer cell lines, and exhibits anti-tumor efficacy in GSI resistant T-ALL cell lines.

CB-103 is a orally active inhibitor of notch signaling pathway, with anti-tumor activity. CB-103 has shown the ability to block NOTCH signaling in human T cell acute lymphoblastic leukemia cancer cell lines, and exhibits anti-tumor efficacy in GSI resistant T-ALL cell lines.CB-103 inhibits growth of GSI/Mab resistant triple negative breast cancer, and exhibits anti-tumor activity in xenograft models of human T-ALL and mouse mammary tumors.(In Vitro):CB-103 acts as a pan-NOTCH inhibitor by targeting NOTCH transcriptional activation complex.CB-103 can block NOTCH signaling in human T cell acute lymphoblastic leukemia cancer cell lines.CB-103 exhibits anti-tumor efficacy in GSI resistant T-ALL cell lines.(In Vivo):CB-103 inhibits NOTCH dependent cellular processes in mice.CB-103 blocks in vivo growth of PDX models of T-ALL.CB-103 (25 mg/kg; i.p./p.o.; 2x daily; for 2 weeks) inhibits growth of GSI/Mab resistant triple negative breast cancer.CB-103 exhibits anti-tumor activity in xenograft models of human T-ALL and mouse mammary tumors.

Limantrafin acts as a pan-NOTCH inhibitor by targeting NOTCH transcriptional activation complex.Limantrafin can block NOTCH signaling in human T cell acute lymphoblastic leukemia cancer cell lines.Limantrafin exhibits anti-tumor efficacy in GSI resistant T-ALL cell lines. Cell Viability Assay Cell Line:RPMI 8402, KOPTK1, PANC1, nRas driven melanoma cells Concentration:10 μM Incubation Time:4 days, 6 days Result:Caused a significant reduction in their growth potential.

Limantrafin inhibits NOTCH dependent cellular processes in mice.Limantrafin blocks in vivo growth of PDX models of T-ALL.Limantrafin (25 mg/kg; i.p./p.o.; 2x daily; for 2 weeks) inhibits growth of GSI/Mab resistant triple negative breast cancer.Limantrafin exhibits anti-tumor activity in xenograft models of human T-ALL and mouse mammary tumors. Animal Model:NSG mice, triple negative breast cancer mouse xenograft model Dosage:25 mg/kg Administration:Oral administration/Intraperitoneal injection; 2x daily; for 2 weeks Result:Inhibited growth of GSI/Mab resistant triple negative breast cancer.

——

Neuroscience

Gamma-secretase

notch

Cancer

Breast Cancer;Colorectal Cancer;Cholangiocellular Carcinoma;Sarcoma;Desmoid Tumour;Adenoid Cystic Carcinoma;Non-hodgkin Lymphoma;Glomus Tumor, Malignant

218457-67-1

242.32

C15H18N2O

>98% (HPLC)

DMSO:230 mg/mL (949.16 mM; Need ultrasonic)

CC(C)(C)c1ccc(Oc2ccc(N)cn2)cc1

——

(-20℃)

With Ice Pack

≥ 2 years